BCIQ Profiles

Company Profile Report
1027 Fin QTs
BioCentury & Getty Images


Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

Oct 28, 2020 | 1:38 AM GMT

Apellis, Sobi enter territorial deal for C3 inhibitor
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) granted Swedish Orphan Biovitrum AB (SSE:SOBI) exclusive

Read the full 474 word article

How to gain access

Continue reading with a
two-week free trial.